Alcon (NYSE:ALC) is a global leader in medical devices and consumer eye care products focused exclusively on vision health. The company designs, develops and manufactures ophthalmic surgical equipment and contact lens products that help prevent, correct and treat disorders of the eye. Serving hospitals, clinics and consumers through a network of direct sales teams and distributors, Alcon’s offerings span advanced surgical platforms, intraocular lenses, contact lenses and lens care solutions.
Its Surgical segment provides platforms for cataract removal—such as phacoemulsification systems and femtosecond lasers—along with intraocular lenses and instrumentation for vitreoretinal and glaucoma procedures. The Vision Care segment includes a broad portfolio of daily disposable, bi-weekly and monthly contact lenses, as well as multipurpose cleaning and disinfecting solutions. Continuous investment in materials science and digital tools supports improved patient outcomes and streamlined clinical workflows.
Founded in 1945 by Gavin S. Herbert in Fort Worth, Texas, Alcon expanded through product innovation and strategic partnerships before becoming part of Novartis in 2010. In April 2019, the company completed a spin-off from Novartis to operate as an independent public company traded on the New York Stock Exchange under the symbol ALC. Headquartered in Geneva, Switzerland, Alcon maintains manufacturing and research facilities across the Americas, Europe and Asia-Pacific, with its products marketed in more than 140 countries.
Under the leadership of CEO David Endicott, Alcon emphasizes research and development, operational excellence and global market expansion. The executive team draws on expertise in medical technology and healthcare to advance next-generation contact lens materials, broaden its surgical portfolio and strengthen partnerships with ophthalmologists and healthcare providers worldwide.
